Drug – bio-affecting and body treating compositions – Conjugate or complex of monoclonal or polyclonal antibody,...
Reexamination Certificate
2006-08-29
2006-08-29
Helms, Larry R. (Department: 1643)
Drug, bio-affecting and body treating compositions
Conjugate or complex of monoclonal or polyclonal antibody,...
C424S130100, C424S135100, C424S141100, C424S155100, C424S158100
Reexamination Certificate
active
07097840
ABSTRACT:
The application concerns methods of treatment using anti-ErbB receptor antibody-maytansinoid conjugates, and articles of manufacture suitable for use in such methods. In particular, the invention concerns ErbB receptor-directed cancer therapies, using anri-ErbB receptor antibody-maytansinoid conjugates.
REFERENCES:
patent: 3896111 (1975-07-01), Kupchan et al.
patent: 4137230 (1979-01-01), Hashimoto et al.
patent: 4151042 (1979-04-01), Higashide et al.
patent: 4248870 (1981-02-01), Miyashita et al.
patent: 4256746 (1981-03-01), Miyashita et al.
patent: 4260608 (1981-04-01), Miyashita et al.
patent: 4265814 (1981-05-01), Hashimoto et al.
patent: 4294757 (1981-10-01), Asai
patent: 4307016 (1981-12-01), Asai et al.
patent: 4308268 (1981-12-01), Miyashita et al.
patent: 4308269 (1981-12-01), Miyashita et al.
patent: 4309428 (1982-01-01), Miyashita et al.
patent: 4313946 (1982-02-01), Powell et al.
patent: 4315929 (1982-02-01), Freedman et al.
patent: 4317821 (1982-03-01), Miyashita et al.
patent: 4322348 (1982-03-01), Asai et al.
patent: 4331598 (1982-05-01), Hasegawa et al.
patent: 4361650 (1982-11-01), Asai et al.
patent: 4362663 (1982-12-01), Kida et al.
patent: 4364866 (1982-12-01), Asai et al.
patent: 4371533 (1983-02-01), Akimoto et al.
patent: 4424219 (1984-01-01), Hashimoto et al.
patent: 4450254 (1984-05-01), Isley et al.
patent: 4968603 (1990-11-01), Slamon et al.
patent: 5183884 (1993-02-01), Kraus et al.
patent: 5208020 (1993-05-01), Chari et al.
patent: 5217713 (1993-06-01), Iwasa et al.
patent: 5416064 (1995-05-01), Chari et al.
patent: 5480968 (1996-01-01), Kraus et al.
patent: 5514554 (1996-05-01), Bacus
patent: 5677171 (1997-10-01), Hudziak et al.
patent: 5705157 (1998-01-01), Greene
patent: 5725856 (1998-03-01), Hudziak
patent: 5747261 (1998-05-01), King et al.
patent: 5772997 (1998-06-01), Hudziak et al.
patent: 5783186 (1998-07-01), Arakawa et al.
patent: 5821337 (1998-10-01), Carter et al.
patent: 5824311 (1998-10-01), Green et al.
patent: 5837234 (1998-11-01), Gentile et al.
patent: 5840525 (1998-11-01), Vandlen et al.
patent: 5877305 (1999-03-01), Huston et al.
patent: 5968517 (1999-10-01), Duncan et al.
patent: 6022541 (2000-02-01), Senger et al.
patent: 6054297 (2000-04-01), Carter et al.
patent: 6436931 (2002-08-01), Chari et al.
Sliwkowski, M.X. et al., J. Biol. Chem. 269(20): 14661-14665, 1994.
Arteaga, C.L. et al., “p185c-erbB-2Signaling Enhances Cisplatin-induced Cytotoxicity in Human Breast Carcinoma Cells: Association between an oncogenic Receptor Tyrosine Kinase and Drug-induced DNA Repair,”Cancer Research,vol. 54, pp. 3758-3765 (1994).
Bacus, S.S. et al., “Tumor-inhibitory Monoclonal Antibodies to the HER-2/Neu Receptor Induce Differentiation of Human Breast Cancer Cells,”Cancer Research,vol. 52, pp. 2580-2589 (1992).
Fendly, B.M. et al., “Characterization of Murine Monoclonal Antibodies Reactive to Either the Human Epidermal Growth Factor Receptor of HER2
eu Gene Product,”Cancer Research,vol. 50, 1550-1558 (1990).
Hancock, M.C. et al., “A Monoclonal Antibody against the c-erbB-2 Protein Enhances the Cytotoxicity of cis-Diamminedichloroplatinum against Human Breast and Ovarian Tumor Cell Lines,” vol. 51, pp. 4575-4580 (1991).
Issell, B.F. et al., “Maytansine,”Cancer Treatment Reviews,vol. 5, pp. 199-207 (1978).
Kasprzyk, P.G. et al., “Therapy of an Animal Model of Human Gastric Cancer Using a Combination of Anti-erbB-2 Monoclonal Antibodies,”Cancer Research,vol. 52, pp. 2771-2776 (1992).
Kern, J.A. et al., “p185neuExpression in Human Lung Adenocarcinomas Predicts Shortened Survival,”Cancer Research,vol. 50, pp. 5184-5191 (1990).
Lewis, G.D. et al., “Growth Regulation of Human Breast and Ovarian Tumor Cells by Heregulin: Evidence for the Requirement of ErbB2 as a Critical Component in Mediating Heregulin Responsiveness,”Cancer Research,vol. 56, pp. 1457-1465 (1996).
Maier, L.A. et al., “Requirement for the Internalization of a Murine Monoclonal Antibody Directed against the HER-2
eu Gene Product c-erbB-2,”Cancer Research,vol. 51, pp. 5361-5369 (1991).
Park, Joo-Bae et al., “Amplification, Overexpression, and Rearrangement of the erbB-2 Protooncogene in Primary Human Stomach Carcinomas,”Cancer Research,vol. 49, pp. 6605-6609 (1989).
Database Chemabs Online! Chemical Abstracts Service, Columbus, Ohio, US; Skrepnik, Nebojsa et al.: “Effects of anti-erbB -2 (HER-2
eu) recombinant oncotoxin Ar209 on human non-small cell lung carcinoma grown orthotopically in athymic nude mice” retreived from STN Database accession No. 126:14452 XP002164007, abstract & Clin. Cancer Res. (1996), 2(11), 1851-1857.
Sarup, J.C. et al., “Characterization of an Anti-p185HER2Monoclonal Antibody that Stimulates Receptor Function and Inhibits Tumor Cell Growth,”Growth Regulation,vol. 1, pp. 72-82 (1991).
Shawver, L.K. et al., “Ligand-like Effects induced by Anti-c-erbB-2 Antibodies Do Not Correlate with and Are Not Required for Growth Inhibition of Human Carcinoma Cells,”Cancer Research,vol. 54, pp. 1367-1373 (1994).
Skrepnik, N. et al., “Effects of Anti-erbB2 (HER-2
eu) Recombinant Oncotoxin AR209 on Human Non-Small Cell Lung Carcinoma Grown Orthotopically in Athymic Nude Mice,”Clinical Cancer Research,vol. 2, pp. 1851-1857 (1996).
Vietta, E.S. et al., “Monoclonal Antibodies as Agonists: An Expanded Role for Their Use in Cancer Therapy,”Cancer Research,vol. 54, pp. 5301-5309 (1994).
Weiner, D.B. et al., “Expression of the neu Gene-encoded Protein (P185neu) in Human Non-Small Cell Carcinomas of the Lung,”Cancer Research,vol. 50, pp. 421-425 (1990).
Yokota, J. et al., “Amplification of c-erbB2 Oncogene in Human Adenocarcinomas in Vivo,”The Lancet,vol. 1, pp. 765-767 (1986).
Yonemura, Y. et al., “Evaluation of Immunoreactivity for erbB-2 Protein as a Marker of Poor Short Term Prognosis in Gastric Cancer,”Cancer Research,vol. 51, pp. 1034-1038 (1991).
Chari, RVJ “Targeted delivery of chemotherapeutics: tumor-activated prodrug therapy,” Advanced Drug Delivery Reviews 31:89-104 (1998).
Spector et al., “Study of the Biologic Effects of Lapatinib, a Reversible Inhibitor of ErbB1 and ErbB2 Tyrosine Kinases, on Tumor Growth and Survival Pathways in Patients With Advanced Malignancies,” Jour. of Clin. Onc. 23(11):2502-2512 (2005).
Blattler Walter
Erickson Sharon
Schwall Ralph
Sliwkowski Mark
Dreger Ginger R.
Fox James A.
Genentech Inc.
Heller Ehrman LLP
Helms Larry R.
LandOfFree
Methods of treatment using anti-ErbB antibody-maytansinoid... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of treatment using anti-ErbB antibody-maytansinoid..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of treatment using anti-ErbB antibody-maytansinoid... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3676970